Invitae
Selling tests below cost to build market share only works if scale eventually produces positive margins. For Invitae, it never did.
Invitae was a Genomics / Diagnostics startup founded in 2010 in USA. It raised $1.2B (plus public market) before collapsing in 2024 — 14 years of runway burned. IdeaProof's AI Failure Score: 90/100, driven by years of negative gross margins on genetic tests, $1.5b+ debt, chapter 11. The shutdown affected employees, investors, and the broader Genomics / Diagnostics ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.
Why did Invitae fail?
Invitae failed in 2024 after 14 years of operation, losing $1.2B (plus public market) in raised capital. The root cause was years of negative gross margins on genetic tests, $1.5b+ debt, chapter 11. Key lesson: Selling tests below cost to build market share only works if scale eventually produces positive margins. For Invitae, it never did.
2010 → 2024
$1.2B (plus public market)
Genomics / Diagnostics
USA
IdeaProof AI Failure Score
What Happened: The Timeline
2010
Invitae founded in San Francisco
Feb 2015
IPO on NYSE
Oct 2020
Acquires ArcherDX for $1.4B in stock+cash deal
Feb 2021
Peak market cap above $9B during biotech boom
2022
$2.2B annual net loss after goodwill impairments
Nov 2023
Delisted from NYSE; market cap below $50M
Feb 13, 2024
Files for Chapter 11 bankruptcy
Apr 2024
Labcorp acquires core diagnostic business for ~$239M
Root Causes
Invitae was founded in 2010 in San Francisco with the mission of bringing genetic testing into 'mainstream medicine' at affordable prices. The company went public on the NYSE in February 2015 and at one point traded at a market cap above $9B in early 2021. Invitae's strategy was deliberate: price tests well below competitors (under $250 for many panels vs. $500–2000 for Myriad Genetics or LabCorp), accept negative gross margins, and bet that volume would eventually produce profitability. It never did. The company posted net losses every single year from inception through 2023, peaking at a $2.2B annual loss in 2022 after major goodwill impairments on a string of acquisitions (ArcherDX in 2020 for $1.4B in particular). Cash burn ran $400–600M annually. By late 2023 Invitae carried more than $1.5B in convertible debt with maturities approaching and no path to refinance. The stock was delisted from the NYSE in November 2023 at a market cap below $50M — more than 99% destruction from peak. Invitae filed for Chapter 11 bankruptcy on February 13, 2024. Labcorp acquired the core diagnostic business for ~$239M in April 2024. The case is now widely cited alongside 23andMe as evidence that the 'consumer genomics' and 'mass-market genetic testing' theses, both venture and public-market, structurally underestimated the cost of running clinical labs at scale.
Key Lessons Learned
2. M&A multiplies risk
The $1.4B ArcherDX acquisition added ~$800M in eventual goodwill impairment to losses that were already structural.
3. Convertible debt is a clock
Invitae's $1.5B convertible debt stack came due against a collapsed equity. With no refinancing path, Chapter 11 was inevitable.
Competitors That Won
Labcorp
Acquired Invitae's core business in April 2024 for $239M
Why they won: Profitable incumbent lab operator with scale and payer relationships
Natera
Public, profitable on adjusted EBITDA basis
Why they won: Focused on higher-margin oncology and reproductive panels, not commodity germline tests
Frequently Asked Questions
Sources & References
Could This Failure Have Been Prevented?
IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Invitae.